Literature DB >> 2655144

Psychophysical changes in glaucoma.

R L Stamper1.   

Abstract

Chronic glaucoma has been thought to spare the central vision until quite late in the disease process. This assumption is based on the use of the relatively insensitive Snellen chart to measure central vision and the relatively sensitive kinetic and static perimetry to measure the peripheral vision. In recent years, new measures of visual function have been utilized to assess patients with glaucomatous damage. Sensitive methods of measuring central visual function such as color vision, contrast sensitivity (both spatial and temporal), and macular light sensitivity have demonstrated defects early in the glaucomatous process - sometimes even before perimetry is affected. Since these visual functions are largely mediated by macular fibers, central vision may be affected earlier and more frequently in glaucoma than previously believed. Studies of both the nerve fiber layer of the retina and of quantitative light sense perimetry suggest that glaucomatous damage may occur diffusely across the population of nerve fibers, focally in the arcuate portion of the nerve fiber layer, or in both places. Color vision, contrast sensitivity and macular light sense appear to correlate with the diffuse type of nerve fiber layer damage. The exact utility of the psychophysical tests that assess central visual function for the clinical management of glaucoma has not yet been demonstrated. More work is needed to determine which tests are most useful, what parameters are most efficient, and what the diagnostic and prognostic significance of abnormal values may be. However, the studies of color vision, contrast sensitivity and macular light sensitivity have led to a better understanding of how glaucoma affects visual function.

Entities:  

Mesh:

Year:  1989        PMID: 2655144

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  14 in total

1.  Association of Vistech contrast sensitivity and visual field findings in glaucoma.

Authors:  W E Sponsel; K L DePaul; J F Martone; M B Shields; A R Ollie; W C Stewart
Journal:  Br J Ophthalmol       Date:  1991-09       Impact factor: 4.638

2.  Association of Structural and Functional Measures With Contrast Sensitivity in Glaucoma.

Authors:  Nima Fatehi; Sara Nowroozizadeh; Sharon Henry; Anne L Coleman; Joseph Caprioli; Kouros Nouri-Mahdavi
Journal:  Am J Ophthalmol       Date:  2017-03-23       Impact factor: 5.258

3.  Correlation of spatial contrast sensitivity and visual fields in glaucoma.

Authors:  M Zulauf; J Flammer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-03       Impact factor: 3.117

4.  Psychophysical testing in glaucoma.

Authors:  K Hitchings
Journal:  Br J Ophthalmol       Date:  1993-08       Impact factor: 4.638

5.  Comparison of contrast sensitivity, visual acuity, and Humphrey visual field testing in patients with glaucoma.

Authors:  J T Wilensky; A Hawkins
Journal:  Trans Am Ophthalmol Soc       Date:  2001

6.  Steady-state pattern electroretinogram following long term unilateral administration of timolol to ocular hypertensive subjects.

Authors:  R Nesher; G L Trick; M A Kass; M O Gordon
Journal:  Doc Ophthalmol       Date:  1990-09       Impact factor: 2.379

7.  Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection.

Authors:  D W Evans; S L Hosking; D Gherghel; J D Bartlett
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

8.  Visual dysfunction in normotensive glaucoma.

Authors:  G L Trick
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

9.  Observations on color vision testing in ocular hypertension and glaucoma.

Authors:  M Mäntyjärvi; M Teräsvirta
Journal:  Int Ophthalmol       Date:  1992-11       Impact factor: 2.031

10.  Early detection of glaucoma by means of a novel 3D computer-automated visual field test.

Authors:  Paul P Nazemi; Wolfgang Fink; Alfredo A Sadun; Brian Francis; Donald Minckler
Journal:  Br J Ophthalmol       Date:  2007-05-15       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.